Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Human normal immunoglobulin may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
This product is a solution containing antibodies. It is prepared from human blood plasma from screened donors and then virally inactivated during manufacture. It is used to protect you against a variety of infections when you have insufficient levels of your own antibodies. This is because you have a condition that prevents you from making your own antibodies, called antibody deficiency. Your doctor will explain further why this medicine has been given to you. Subgam is given by injection just under the skin (subcutaneously). Your doctor or nurse will give you the injection or instruct you in how to inject yourself. 2.
e Subgam
Do not use Subgam: –
if you are allergic to human immunoglobulins or to any of the other ingredients of this medicine (listed in section 6) if you are suffering from any blood disorders which interfere with clotting as this medicine may cause severe bruising where injected into a blood vessel (intravenously)
Check with your doctor if you think this applies to you.
1
Warnings and precautions Talk to your doctor, pharmacist or nurse before using Subgam:
2
Other medicines and Subgam Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines including those obtained without a prescription. Tell your doctor or nurse about your treatment with Subgam if any vaccination is being planned. You must not mix other medicines with Subgam. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before this medicine is injected. Driving and using machines The ability to drive and operate machines may be impaired by some adverse reactions associated with Subgam. If you experience adverse reactions during treatment, wait for these to resolve before driving or operating machines. Subgam contains sodium and polysorbate Sodium This medicinal product contains up to 0.2 mmol (4.6 mg) sodium per ml (main component of cooking/table salt). To be taken into consideration by patients on a controlled sodium diet. Polysorbate Subgam 750 mg contains 0.1 mg of polysorbate 80 in each 5 ml which is equivalent to 0.02 mg/ml. Subgam 1 g contains 0.13 mg of polysorbate 80 in each 6.25 ml which is equivalent to 0.02 mg/ml. Subgam 1500 mg contains 0.2 mg of polysorbate 80 in each 10 ml which is equivalent to 0.02 mg/ml. Subgam 2 g contains 0.25 mg of polysorbate 80 in each 12.5 ml which is equivalent to 0.02 mg/ml. Subgam 4 g contains 0.5 mg of polysorbate 80 in each 25 ml which is equivalent to 0.02 mg/ml. Polysorbates may cause allergic reactions. Tell your doctor if you have or your child has any known allergies. 3.
Subgam
Always use this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure. Subgam must not be injected into a vein. It must be injected slowly just under the skin. This product may be injected by yourself. Injection of this product under the skin requires either an infusion device, usually a "syringe driver", or can be administered directly with a syringe and needle. Your doctor or nurse can discuss these options with you and will train you. You will only be allowed to inject yourself just under the skin. Doses Your doctor will advise you on the dose and dose frequency for you, which might mean having a blood test to measure the amount of antibodies in your blood. At the start of treatment at least 0.2 – 0.5 g/kg body weight may be given. When normal levels of antibodies have been reached in your blood stream, the regular dose will be about 100 mg/kg usually weekly. Alternative frequencies may be suitable for you and your doctor or nurse can discuss these options with you. 3
Instructions for use The following table gives instructions for use, either with an infusion device or injecting directly with a syringe and needle. The initial steps 1 to 3 are the same for both options. Then steps 4 to 9 are separated to describe how to correctly use the different equipment needed for each technique.
4
Initial steps Step 1: Preparation • •
•
Bring Subgam to room temperature – do not apply heat or place in a microwave. Clean the work area and gather the items needed:
Step 2: Check the vials of Subgam solution
5
Instructions for use with an Infusion Device
Instructions for use with Syringe and Needle
Step 4: Prepare the infusion device
Step 4: Prepare the syringe for injection
Step 5: Prepare the infusion site(s)
Step 5: Prepare the injection site(s)
Step 6: Insert and secure the subcutaneous needle set
Step 6: Insert the subcutaneous needle
6
Step 7: Start the infusion
Step 7: Start the injection
Step 8: Complete the infusion and remove the needle(s) from the infusion site(s)
Step 8: Complete the injection and remove the needle(s) from the injection site(s)
Step 9: Record the treatment
Step 9: Record the treatment
Figures:
Figure 1
Figure 2
Figure 3
Figure 4
Tell your nurse about any problems you have during your infusions/injections. Your nurse may ask to see your infusion diary so take it with you each time you visit them. For further information and to download a Subgam Infusion Diary, visit www.subgam.co.uk. If you use more Subgam than you should If you think that you have used more Subgam than you should, speak to your doctor, pharmacist or nurse as soon as possible. 7
If you forget to use Subgam Do not take a double dose to make up for a forgotten dose. If you think that you have missed a dose speak to your doctor, pharmacist or nurse as soon as possible. If you stop using Subgam You are more likely to have more infections, some of which may be severe. Therefore, speak to your doctor, pharmacist or nurse if you think you ought to stop Subgam. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects have been reported with Subgam. Rarely (may affect up to 1 in 1,000 people) human normal immunoglobulins may cause an allergic reaction (for example, sudden fall in blood pressure, dizziness, lightheadedness, fast heart rate, chest pain, blurred vision) and in some cases shock (loss of consciousness). Stop using the medicine immediately and tell your doctor or nurse straight away. Some short-term discomfort at the site of injection such as swelling, hardening around the injection site, soreness, redness, itching, bruising, rash and feeling hot to touch may be experienced. This local reaction is very common at the start of treatment but reduces as further injections are given. Very common (may affect more than 1 in 10 people):
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. 5.
Subgam
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the containers after "EXP". The expiry date refers to the last day of that month. Store in a refrigerator (2°C – 8°C). Do not freeze. Subgam may be stored for two months at room temperature (up to 25°C) • If stored at room temperature for up to one week, you may return the product to the refrigerator with no change to the expiry date • After two months at room temperature, any unused product should be discarded. Once the carton has been removed from the refrigerator, the date should be recorded. Keep the vial in the outer carton in order to protect from light. Do not use this medicine if it is cloudy or if any small bits can be seen in it. Disposal After injection of the correct dose, your doctor or nurse will dispose of any solution that remains, along with used syringes, needles and containers. If you are using this medicine at home ask your doctor for a container to dispose material in and take the container back to your doctor when full. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Subgam contains –
The active substance is human normal immunoglobulin. One ml contains 160 mg of human plasma protein, of which at least 95% is immunoglobulin type G (IgG).
–
This medicine contains trace elements of IgA (not more than 0.064 milligrams/ml).
–
The other ingredients are: glycine, sodium chloride, sodium acetate and polysorbate 80.
What Subgam looks like and contents of the pack Subgam is a clear or colourless to slightly pearl-like (opalescent) solution, available as single dose glass vials containing antibodies. Pack sizes Subgam 750 mg: 1 vial contains 5 ml solution for injection Subgam 1 g: 1 vial contains 6.25 ml solution for injection 9
Subgam 1500 mg: 1 vial contains 10 ml solution for injection Subgam 2 g: 1 vial contains 12.5 ml solution for injection Subgam 4 g: 1 vial contains 25 ml solution for injection Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Bio Products Laboratory Ltd Elstree WD6 3BX United Kingdom For any information about this medicine, please contact the Marketing Authorisation Holder. Please e-mail: [email protected] This leaflet was last revised in September 2024.
10
Version 14
Subgam, Human normal immunoglobulin solution comes as solution. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Subgam, Human normal immunoglobulin solution is human normal immunoglobulin.
This leaflet reproduces the patient information leaflet approved for Subgam, Human normal immunoglobulin solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Indications for subcutaneous administration (SCIg)
Replacement therapy in adults, children and adolescents (0-18 years) in:
• Primary immunodeficiency syndrome with impaired antibody production (see section 4.4).
• Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated.
• Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients.
• Hypogammaglobulinaemia in patients pre- and post-allogeneic haematopoietic stem cell transplantation (HSCT).
Replacement therapy should be initiated and monitored under the supervision of a physician experienced in the treatment of immunodeficiency.
Posology
Replacement therapy
The product should be administered via the subcutaneous route.
In replacement therapy the dose may need to be individualised for each patient dependent on the pharmacokinetic and clinical response. The following dose regimens are given as a guideline.
The dose regimen should achieve a trough level of IgG (measured before the next infusion) of at least 6 g/l and aim to be within the reference interval of serum IgG for age. A loading dose of at least 0.2 to 0.5 g/kg (1.25 to 3.13 ml/kg) may be required. This may need to be divided over several days, with a maximal daily dose of 0.1 to 0.15 g/kg.
After steady state IgG levels have been attained, maintenance doses are administered at repeated intervals to reach a cumulative monthly dose of the order of 0.4 ‑ 0.8 g/kg. Each single dose may need to be injected at different anatomic sites.
Trough levels should be measured and assessed in conjunction with the incidence of infection. To reduce the rate of infection, it may be necessary to increase the dose and aim for higher trough levels.
Paediatric population
The posology in children and adolescents (0-18 years) is not different to that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome in replacement therapy indications.
Method of administration
For subcutaneous use only.
Subcutaneous infusion for home treatment should be initiated and monitored by a physician experienced in the guidance of patients for home treatment. The patient will be instructed in the use of appropriate infusion devices, or other infusion techniques, the keeping of a treatment diary and measures to be taken in case of severe adverse reactions.
Subgam may be injected into sites such as abdomen, thigh, upper arm, and lateral hip by (a) an infusion device or
(b) manual push using a syringe and needle
Infusion device
It is recommended to use an initial administration speed of between 10 to 20 ml/h/site.
If well tolerated (see section 4.4), the infusion speed can be increased to a recommended maximum speed of 30 ml/h/site. More than one infusion device can be used simultaneously. The amount of product infused into a particular site varies. In infants and children, infusion site may be changed every 5-15 ml. In adults, doses over 30 ml may be divided according to patient preference. There is no limit to the number of infusion sites.
Manual push using a syringe and needle
For practical reasons, a single site per syringe is recommended. The rate of administration should be adjusted for each patient's local tolerance which may depend on the volume and site of each subcutaneous injection and the amount of the individual patient's subcutaneous tissue at that site. If well tolerated, the infusion rate can be increased with subsequent doses.
An appropriate choice of needle size may facilitate achievement of infusion rate.
Frequency of infusions
When tailoring the dosage regimen for an individual, the following are recommended dosage administrations (see section 5.2).
- Daily:
- Three times each week:
- Twice weekly:
- Once every two weeks:
weekly dose divided by 7;
weekly dose divided by 3
weekly dose divided by 2
weekly dose multiplied by 2.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section 4.4).
Subgam must not be given intravenously.
Subgam must not be administered intramuscularly in cases of severe thrombocytopenia and in other disorders of haemostasis.
If Subgam is accidentally administered into a blood vessel, patients could develop shock.
The recommended infusion rate given under section 4.2 must be closely followed. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period.
Certain adverse reactions may occur more frequently in patients who receive human normal immunoglobulin for the first time or, in rare cases, when the human normal immunoglobulin product is switched or when there has been a long interval since the previous infusion.
Potential complications can often be avoided by:
• initially injecting the product slowly (0.002 ml/kg/min)
• ensuring that patients are carefully monitored for any symptoms throughout the infusion period. In particular, patients naïve to human normal immunoglobulin, patients switched from an alternative immunoglobulin product or when there has been a long interval since the previous infusion should be monitored during the first infusion and for the first hour after the first infusion, in order to detect potential adverse signs.
All other patients should be observed for at least 20 minutes after administration.
In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped. The treatment required depends on the nature and severity of the adverse reaction.
In case of shock, standard medical treatment should be administered.
Hypersensitivity
True allergic reactions are rare. They can particularly occur in patients with anti-IgA antibodies who should be treated with particular caution. Patients with anti-IgA antibodies, in whom treatment with subcutaneous IgG products remains the only option, should be treated with Subgam only under close medical supervision.
Rarely, human normal immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who had tolerated previous treatment with human normal immunoglobulin.
Thromboembolism
Arterial and venous thromboembolic events including myocardial infarction, stroke, deep venous thrombosis and pulmonary embolism have been associated with the use of immunoglobulins. Patients should be sufficiently hydrated before use of immunoglobulins. Caution should be exercised in patients with pre-existing risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic events, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilisation, severely hypovolemic patients, patients with diseases which increase blood viscosity).
Patients should be informed about first symptoms of thromboembolic events including shortness of breath, pain and swelling of a limb, focal neurological deficits and chest pain and should be advised to contact their physician immediately upon onset of symptoms.
Aseptic Meningitis Syndrome (AMS)
Aseptic meningitis syndrome has been reported to occur in association with subcutaneous immunoglobulin treatment; the symptoms usually begin within several hours to 2 days following treatment. Discontinuation of immunoglobulin treatment may result in remission of AMS within several days without sequelae.
Patients should be informed about first symptoms which encompass severe headache, neck stiffness, drowsiness, fever, photophobia, nausea and vomiting.
Important information about excipients of Subgam
Sodium
This medicinal product contains up to 4.6 mg sodium per ml, equivalent to 2.5% of the WHO recommended maximum daily intake of 2 g sodium for an average 80kg adult.
Polysorbate
Subgam 750 mg contains 0.1 mg of polysorbate 80 in each 5 ml which is equivalent to 0.02 mg/ml.
Subgam 1500 mg contains 0.2 mg of polysorbate 80 in each 10 ml which is equivalent to 0.02 mg/ml.
Subgam 1 g contains 0.13 mg of polysorbate 80 in each 6.25 ml which is equivalent to 0.02 mg/ml.
Subgam 2 g contains 0.25 mg of polysorbate 80 in each 12.5 ml which is equivalent to 0.02 mg/ml.
Subgam 4 g contains 0.5 mg of polysorbate 80 in each 25 ml which is equivalent to 0.02 mg/ml.
Polysorbates may cause allergic reactions. Tell your doctor if you have or your child has any known allergies.
Interference with serological testing
After injection of immunoglobulin the transitory rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing.
Passive transmission of antibodies to erythrocyte antigens, e.g. A, B, D may interfere with some serological tests for red cell antibodies for example the direct anti-globulin test (DAT, direct Coombs' test).
Transmissible agents
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) and for the non-enveloped hepatitis A and parvovirus B19 viruses.
There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to the viral safety.
It is strongly recommended that every time that Subgam is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.
Paediatric population
The listed warnings and precautions apply to both adults and children.
Live attenuated virus vaccines
Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella. After administration of this medicinal product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year. Therefore, patients receiving measles vaccine should have their antibody status checked.
Paediatric population
The listed interactions apply to both adults and children.
Pregnancy
The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. Immunoglobulin products have been shown to cross the placenta, increasingly during the third trimester. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected.
Breast-feeding
Immunoglobulins are excreted into the milk and may contribute to protecting the neonate from pathogens which have a mucosal portal of entry.
Fertility
Clinical experience with immunoglobulins suggests that no harmful effects are to be expected.
The ability to drive and operate machines may be impaired by some adverse reactions associated with Subgam. Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.
Summary of the safety profile
Adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Rarely human normal immunoglobulins may cause a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.
Local reactions at infusion sites: swelling, soreness, redness, induration, local heat, itching, bruising and rash may frequently occur.
For safety information with respect to transmissible agents, see section 4.4.
Tabulated list of adverse reactions
The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).
Frequencies have been evaluated according to the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1,1000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Frequency of Adverse Reactions (ADRs) in clinical studies with Subgam
MedDRA System Organ Class (SOC)
Adverse reaction
Frequency
Psychiatric disorders
Anxiety
Common
Nervous system disorders
Headache
Dizziness
Migraine
Paraesthesia
Very common
Common
Common
Common
Vascular disorders
Flushing
Common
Respiratory, thoracic and mediastinal disorders
Wheezing/asthma
Common
Gastrointestinal disorders
Nausea
Vomiting
Diarrhoea
Mouth ulcer
Abdominal pain upper
Common
Common
Common
Common
Common
Skin and subcutaneous tissue disorders
Pruritus
Sweating increased
Rash
Common
Common
Common
Musculoskeletal, connective tissue and bone disorders
Arthralgia
Musculoskeletal pain/stiffness
Common
Common
General disorders and administration site conditions
Infusion site reaction
Chest pain/tightness
Fatigue
Pyrexia
Shivering/feeling cold
Very common
Common
Common
Common
Common
Investigations
Blood pressure increased
Common
Description of selected adverse reactions
Although infusion site reactions are very common initially, their frequency usually reduces with continued treatment aided by changing the sites of infusions.
Paediatric population
Frequency, type and severity of adverse reactions in children are the same as in adults.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard
Consequences of an overdose are not known.
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Subgam, Human normal immunoglobulin solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.